Starting January 1, 2026 C.E., California will sell state-branded insulin pens directly to residents for a maximum of $55 for a five-pack — just $11 per pen. The announcement marks the first time a U.S. state has manufactured and sold its own low-cost insulin, using a publicly backed program to undercut pharmaceutical prices that can run four to seven times higher for the same medication.
At a glance
- CalRx insulin: California’s state-backed program will sell biosimilar long-acting insulin glargine pens at a maximum retail price of $55 for a five-pack, compared to brand-name equivalents that can cost pharmacies up to $411 per pack.
- Civica Rx contract: The state signed a $50 million contract with nonprofit manufacturer Civica Rx, which subcontracted with Biocon Biologics to produce the insulin — sold to pharmacies at $45 per five-pack before the $55 retail cap.
- Co-pay cap: A separate new California law limits consumer insulin co-payments to $35 per month, adding a second layer of protection for insured residents alongside the state-manufactured supply.
Why insulin prices got this high
Insulin has been around for over a century. The scientists who first isolated it in 1921 C.E. sold the patent for one dollar each, intending the drug to stay accessible forever. That plan did not survive contact with the American pharmaceutical market.
A handful of large companies came to dominate global insulin production, and U.S. prices climbed to among the highest in the world. A 2022 C.E. survey by Charity Rx found that nearly 80% of American insulin users said the drug’s price had created financial hardship for themselves or someone they care for. People have rationed doses, skipped injections, and died from complications that a $11 pen could have prevented.
Diabetes affects more than 38 million Americans — over 11% of the population — and falls hardest on Black, Hispanic, and Native American communities, who face higher rates of the disease and steeper barriers to consistent care. Cost is among the most actionable of those barriers.
How the CalRx model works
California’s CalRx program, launched in 2020 C.E., contracts with manufacturers to produce generic and biosimilar pharmaceuticals, then sells them at near-cost prices. For insulin, the state partnered with Civica Rx — a nonprofit formed by a coalition of health systems specifically to combat drug shortages and high prices.
Civica Rx’s Virginia manufacturing plant will eventually produce three common insulin types: glargine, aspart, and lispro. The California rollout begins with a long-acting biosimilar glargine pen produced by Biocon Biologics. Separately, Civica Rx is also offering the five-pack nationwide starting in January through a partnership with Blue Cross Blue Shield.
The CalRx program previously made naloxone nasal spray available at a discounted $24 for a twin pack to consumers, and free to eligible organizations. Insulin is its most significant product yet by scale of potential impact.
“California didn’t wait for the pharmaceutical industry to do the right thing — we took matters into our own hands,” Governor Gavin Newsom said in a statement. “No Californian should ever have to ration insulin or go into debt to stay alive.”
What experts are saying
The American Diabetes Association called the program “an important, incremental step to offer more options for affordable insulin.” Christine Fallabel, the ADA’s director of State Government Affairs and a person living with type 1 diabetes, told Healthline that the organization applauds any effort to improve affordability for people who depend on insulin to survive.
Kanwar Kelley, MD, co-founder of Side Health in Orinda, California, called the program promising — and noted that capping individual out-of-pocket costs could push other manufacturers to lower their own prices, reducing the need for coupons and savings programs that often require patients to navigate complex paperwork just to afford a basic medication.
Kelley also raised legitimate concerns worth watching. If demand for the lower-priced CalRx insulin is high — which seems likely — Civica Rx will need to scale production quickly to avoid shortfalls. Some patients may also be reluctant to switch from insulin brands they’ve used for years, even if the biosimilar is clinically equivalent. And if other manufacturers reduce their production in response to lost market share, the overall insulin supply could face pressure.
A model other states are watching
Several states have already passed laws capping out-of-pocket insulin costs, and the federal government set a $35 monthly Medicare co-pay cap under the Inflation Reduction Act. But patient cost caps don’t fix what the broader system pays — and those upstream costs drive insurance premiums, Medicaid budgets, and employer health plans alike.
State-backed manufacturing is a more direct intervention. If CalRx proves that a state government can produce and distribute a complex pharmaceutical product reliably and affordably, it opens the door for similar programs targeting other high-cost drugs — EpiPens, certain cancer treatments, and other medications where patent protections and market consolidation have pushed prices far beyond manufacturing costs.
“California is a big market state that has considerable tax revenue to be able to implement this plan; other states may not be able to do so on the same scale,” Kelley noted. But he added that the federal government’s interest in lowering prescription drug prices could help other states adopt similar models over time. For the 3.2 million Californians living with diabetes, the question of whether the model scales nationally matters — but it’s secondary to whether the $11 pen arrives on time at their pharmacy in January.
You can learn more about how states and communities are building equitable access to essential resources through the Good News for Humankind archive on global health.
Read more
For more on this story, see: Healthline
For more from Good News for Humankind, see:
- Renewables now make up at least 49% of global power capacity
- Marie-Louise Eta becomes the first female head coach in men’s top-flight European football
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
COP30 pledges recognition of 160 million hectares of Indigenous land rights
At the COP30 World Leaders Summit in Belém, Brazil in November 2025, 15 governments pledged to formally recognize Indigenous land rights over 160 million hectares by 2030 — an area the size of Iran — through the Intergovernmental Land Tenure Commitment. Brazil committed at least 59 million hectares. More than 35 donors renewed a $1.8 billion Forest and Land Tenure Pledge. The Tropical Forest Forever Facility secured nearly $7 billion, with 20% directed to Indigenous peoples. It was the largest Indigenous participation in COP history.
-
Ghana declares its first marine protected area to rescue depleted fish stocks
Ghana’s marine protected area — the country’s first ever — marks a historic turning point for a nation gripped by a quiet fisheries crisis. Established near Cape Three Points in the Western Region, the protected zone restricts or bans fishing activity to allow severely depleted fish populations to recover. Ghana’s coastal stocks have fallen by an estimated 80 percent from historic levels, threatening food security and the livelihoods of millions of small-scale fishers. The declaration also carries regional significance, potentially inspiring neighboring Gulf of Guinea nations to establish coordinated protections of their own.
-
U.S. researchers cut Alzheimer’s risk by half in first-ever prevention trial
Alzheimer’s prevention may have reached a turning point after a landmark trial showed that removing amyloid plaques before symptoms appear can cut the risk of developing the disease by roughly 50%. Researchers at Washington University School of Medicine studied people with rare genetic mutations that make Alzheimer’s nearly inevitable, finding that early, aggressive treatment can genuinely alter the disease’s course. The results, published in The Lancet Neurology, mark the first time any intervention has shown potential to prevent Alzheimer’s from appearing at all, not merely slow its progression. That distinction matters enormously, since amyloid begins accumulating in the brain two…
